Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Analyst
Daina Graybosch
Period: Reporting periods mapped to calendar 2024 Q4 – 2026 Q1 (6 quarters).
- Questions
- 9on tracked calls
- Challenge rate
- 0%none of 9 questionsLimited sample
- Companies
- 2questioned at least once
- Reporting periods
- 6with questions
These figures cover the whole profile: every tracked question, all reporting periods.
How to read these numbers
Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.
Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.
No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.
Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.
Small samples. Profiles with fewer than 10 questions are marked Limited sample.
Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.
Questions asked
Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.
Showing 9 of 9 questions from 2 companies
MRKMerck & Co., Inc.5 questions · 5 reporting periods · 0 of 5 challenging
Calendar 2026 Q1
what should we keep in mind as we look at those outcomes on how it could or could not translate globally
Show response
Dean Li acknowledged China data may not translate directly but emphasized sac-TMT differentiation, noting the global Phase III program includes 17 studies with 50% evaluating KEYTRUDA combos.
Calendar 2025 Q4
I wonder if you could update us on your biomarker strategy. Given a TROP-two ADC competitor
Show response
Dean said biomarker use will be context-dependent by tumor type and comparator, confirming Merck is 'cooking something' on biomarker strategy without committing to specific Phase III implementations.
Calendar 2025 Q3
an update on KEYTRUDA and the proportion of the sales that you have from early-stage settings
Show response
Rob confirmed earlier-stage indications now exceed the 25% target set for 2024/2025 and drive over half of KEYTRUDA growth, led by cervical, RCC, TNBC and NSCLC.
Calendar 2025 Q2
What's your bar for success on both of those? And if you replicate those outcomes in Phase III
Show response
Dean framed PVR as the key signal for CADENCE in a PH-physiology heart failure population and said the FDA would likely still require a Phase III for registration.
Calendar 2024 Q4
Can you help us understand what outcomes you may be able to provide from that trial given the enrollment
Show response
Dean pivoted to a pipeline overview and said the HYPERION study remains blinded, with no specific outcome commitment.
GILDGilead Sciences4 questions · 4 reporting periods · 0 of 4 challenging
Calendar 2025 Q4
what gives you confidence in a second-half launch? Does that assume priority review for FDA
Show response
Cindy could not confirm priority review status but expressed confidence based on FDA conversations around the filing. iMMagine-3 has dual primary endpoints of MRD and PFS, consistent with recent FDA guidance.
Calendar 2025 Q3
I wonder if you could give us a little more detail to how much of the lives have prior auths or co-pay or any other restrictions
Show response
Johanna disclosed high 80s percent of plans have zero co-pays with very few step edits or prior auths. Cited Descovy benchmark: 99% access with 88% unrestricted. Emphasized quality of access, not just breadth.
Calendar 2025 Q1
the process to add lenacapavir to the USPSTF mandate for coverage about cost sharing
Show response
Johanna acknowledged USPSTF addition takes time but said launch plans don't depend on it. IAS guidelines already include lenacapavir pre-approval. Value proposition drives initial access.
Calendar 2024 Q4
if you could give us your reflections on the competitiveness of the late-stage oncology portfolio
Show response
Dietmar highlighted Trodelvy's differentiated OS benefit and Phase 3 readouts coming in 2025. Described TIGIT as an interesting target with encouraging early data but pending Phase 3 confirmation.
Challenge rate by company
Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.
| Company | Questions | Challenge rate |
|---|---|---|
| MRK Merck & Co., Inc. | 5 | 0%none of 5 questions |
| GILD Gilead Sciences | 4 | 0%none of 4 questions |
Activity by reporting period
Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.
| Calendar period | Questions | Challenge rate | Companies |
|---|---|---|---|
| 2024 Q4 | 2 | 0%none of 2 questions | 2 |
| 2025 Q1 | 1 | 0%none of 1 question | 1 |
| 2025 Q2 | 1 | 0%none of 1 question | 1 |
| 2025 Q3 | 2 | 0%none of 2 questions | 2 |
| 2025 Q4 | 2 | 0%none of 2 questions | 2 |
| 2026 Q1 | 1 | 0%none of 1 question | 1 |
- 2024 Q42 questions · challenge rate 0% (none of 2 questions) · 2 companies
- 2025 Q11 question · challenge rate 0% (none of 1 question) · 1 company
- 2025 Q21 question · challenge rate 0% (none of 1 question) · 1 company
- 2025 Q32 questions · challenge rate 0% (none of 2 questions) · 2 companies
- 2025 Q42 questions · challenge rate 0% (none of 2 questions) · 2 companies
- 2026 Q11 question · challenge rate 0% (none of 1 question) · 1 company
Topics
Topics tagged on this analyst’s questions.
- Innovation & R&D6
- Product Launch3
- Regulation Policy2
- Competitive Dynamics2
- Geographic Expansion1
- Pricing1
- Revenue Growth1